Drug Search Results
More Filters [+]

Entecavir

Alternative Names: entecavir, baraclude
Latest Update: 2024-09-18
Latest Update Note: Clinical Trial Update

Product Description

Entecavir is used to treat chronic (long-term) hepatitis B infection (swelling of the liver caused by a virus) in adults and children 2 years of age and older who have liver damage. Entecavir is in a class of medications called nucleoside analogs. It works by decreasing the amount of hepatitis B virus (HBV) in the body. Entecavir does not cure HBV and may not prevent complications of chronic hepatitis B such as cirrhosis of the liver or liver cancer. Entecavir does not prevent the spread of HBV to other people (Sourced from: https://medlineplus.gov/druginfo/meds/a605028.html)

Mechanisms of Action: Nucleoside Polymerase Inhibitor,HBV-NART Inhibitor,NRT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Entecavir

Countries in Clinic: Australia, Belgium, Canada, China, France, Germany, Italy, Korea, New Zealand, Poland, Spain, Taiwan, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 22

Highest Development Phases

Phase 3: Hepatitis B, Chronic

Phase 2: Hepatitis A|Herpesviridae Infections|Inflammation|Liver Cirrhosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ANRS HB07 IP-cure-B

P2

Active, not recruiting

Hepatitis B, Chronic

2024-02-01

HEC160208-HBV-101

P1

Completed

Hepatitis B, Chronic|Hepatitis A

2023-01-17

21%

APG1387BC201

P2

Recruiting

Hepatitis B, Chronic|Hepatitis A

2022-10-31

24%

APG1387BC201

P2

Recruiting

Hepatitis B, Chronic|Hepatitis A

2022-10-31

24%

CTR20181151

P2

Completed

Hepatitis B, Chronic|Liver Cirrhosis

2022-06-28

Recent News Events